Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Accenture
Farmers Insurance
Queensland Health
Deloitte
Chinese Patent Office
Novartis
Johnson and Johnson
Cipla
Chubb

Generated: January 18, 2018

DrugPatentWatch Database Preview

INLYTA Drug Profile

« Back to Dashboard

Which patents cover Inlyta, and when can generic versions of Inlyta launch?

Inlyta is a drug marketed by Pf Prism Cv and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and seven patent family members in fifty-three countries.

The generic ingredient in INLYTA is axitinib. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the axitinib profile page.
Summary for INLYTA
International Patents:107
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Bulk Api Vendors: 86
Clinical Trials: 23
Patent Applications: 106
Drug Prices:see details
DailyMed Link:INLYTA at DailyMed
Drug patent expirations by year for INLYTA
Pharmacology for INLYTA

US Patents and Regulatory Information for INLYTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-001 Jan 27, 2012 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-002 Jan 27, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-001 Jan 27, 2012 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-002 Jan 27, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-001 Jan 27, 2012 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-001 Jan 27, 2012 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-002 Jan 27, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-002 Jan 27, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for INLYTA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,531,491 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use ➤ Subscribe
6,884,890 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use ➤ Subscribe
7,141,587 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use ➤ Subscribe
6,891,044 Indazole compounds and pharmaceutical compositions for Inhibiting protein kinases, and methods for their use ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for INLYTA

Supplementary Protection Certificates for INLYTA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013 00010 Denmark ➤ Subscribe
154 Luxembourg ➤ Subscribe PRODUCT NAME: AXITINIB, EVENTUELLEMENT SOUS LA FORME D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE
00576 Netherlands ➤ Subscribe PRODUCT NAME: AXITINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/12/777/001-006 20120903
2013003,C1218348 Lithuania ➤ Subscribe PRODUCT NAME: AXITINIBUM; REGISTRATION NO/DATE: EU/1/12/777/001 - EU/1/12/777/006 20120903
1218348/01 Switzerland ➤ Subscribe PRODUCT NAME: AXITINIB; NAT. REGISTRATION NO/DATE: SWISSMEDIC 62281 20120410
8 Finland ➤ Subscribe
2013000016 Germany ➤ Subscribe PRODUCT NAME: AXITINIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; REGISTRATION NO/DATE: EU/1/12/777/001-006 20120903
90007-1 Sweden ➤ Subscribe PRODUCT NAME: AXITINIB, VALFRITT I FORM AV ETT FARMACEUTISKT GODTAGBART SALT; REG. NO/DATE: EU/1/12/777/001 20120903
2013003 Lithuania ➤ Subscribe PRODUCT NAME: AXITINIBUM; REGISTRATION NO/DATE: EU/1/12/777/001 - EU/1/12/777/006 20120903
C0010 France ➤ Subscribe PRODUCT NAME: AXITINIB, ET OPTIONNELLEMENT SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/777/001 20120903
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Moodys
Julphar
Novartis
Deloitte
AstraZeneca
Boehringer Ingelheim
Daiichi Sankyo
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot